Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Sophion and ChanTest announce ion channel cell line collaboration

Vancouver, BC (June 24, 2008). Today, Sophion Bioscience and ChanTest Corporation announced a landmark agreement regarding ion channel cell lines for ion channel drug discovery and safety testing at the 6th Annual Ion Channel Retreat. Under the terms of this agreement, Sophion has the right to provide ion channel cell lines from ChanTest that are optimized for Sophion’s QPatch automated patch clamp systems.

“We are thrilled to partner with Sophion in the process of optimizing the automated patch clamp world,” said Dr. Arthur “Buzz” Brown, CEO of ChanTest. “The combination of our extensive ion channel cell line library and Sophion’s Qpatch systems is new and has the potential to revolutionize the drug discovery process.”

Dr. Morten Sunesen, Sophion’s Director of Customer Relations, added, “A critical aspect of a thriving QPatch assay relates to having optimized cell lines. This partnership between Sophion and ChanTest allows Pharma and Biotech groups in the ion channel drug discovery industry to quickly get usable data with a great variety of ion channel cell lines.”

About Sophion Bioscience

Sophion Bioscience, a leader in the automated patch clamp field, helps drug discovery companies make more and better drugs, faster. Sophion’s sole focus is to provide advanced products and integrated solutions for automated patch clamping Sophion’s QPatch 16 and QPatch HT (48-channels) provide high-quality patch clamp data on a truly industrial basis. Only the QPatch has an integrated cell preparation and QPlate exchange facilities enabling several hours of unattended operation. The unique microfluidic flow channel system implemented in the QPlates enables fast liquid exchange around each cell and provides the option to test multiple compounds or increasing concentrations on the same cell.

About ChanTest

ChanTest is the preeminent ion channel services company. ChanTest has tested more than 13,000 compounds for more than 300 clients around the world – pharmaceutical and biotech companies large and small. In HTStec Ion Channel Trends Surveys for 2006 and 2007, ChanTest was voted the “world’s most trusted ion channel services company”. ChanTest is building and validating the most complete ion channel library extant. “Books” in the library are optimized on Qpatch HT and all other major automated electrophysiology platforms. The ion channel “books” can be arranged in panels according to tissue (cardiac channel panel), therapeutic area (pain channel panel) and ion channel families (Nav1.x channel panel). These panels are used in preclinical profiling and risk assessment of the heart and cardiovascular system, CNS, and respiratory, G-I and G-U systems.

For more information, please contact: Morten Sunesen, Ph.D., Director, Customer
Relations, Sophion Bioscience A/S, e-mail: or telephone: +45-
4460-8866 or Robert D. Schultek, Vice President, Business Development, ChanTest
Corporation, email: or telephone: +1 216-332-1665.

Publisher Contact Information:

Sophion Bioscience A/S

Company profile of Sophion Bioscience A/S
Past press releases of Sophion Bioscience A/S.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.